Q-omics provides the consensus-scored NUTM2A profile across patient tissues and cancer cell-line models. NUTM2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NUTM2A is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, NUTM2A RNA expression shows 17,589 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, COAD, and UVM as cancer lineages where NUTM2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTM2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTM2A survival associations across molecular data types. NUTM2A RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTM2A RNA expression–survival associations across cancer types. High NUTM2A expression shows unfavorable associations in HNSC and THCA, but favorable associations in UCS, LGG, BRCA and UCEC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify UCS as the clearest survival context for NUTM2A RNA expression.
This table summarizes NUTM2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NUTM2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTM2A shows lower tumor expression in COAD, KICH and THCA and higher tumor expression in LIHC, HNSC and CHOL. The COAD box plot shows higher NUTM2A RNA expression in normal versus tumor tissue (log2 FC = −0.244, t-test p < 0.001).
This table shows molecular features associated with NUTM2A in patient tissues and cancer cell lines. In patient samples, NUTM2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUTM2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
